• Worapot Treamtrakanpon, Pornpen Tantivitayakul, Thitima Benjachat, Poorichaya Somparn, Wipawee Kittikowit, Somchai Eiam-ong, Asada Leelahavanichkul, Nattiya Hirankarn, and Yingyos Avihingsanon.
• Arthritis Res. Ther. 2012 Nov 21; 14 (6): R252.

IntroductionBLyS and APRIL are cytokines from the tumor necrosis factor family which play an important role in systemic lupus erythematosus (SLE). Previous works suggested an association between both molecules and SLE disease activity although their correlation with lupus nephritis is not known. We therefore assessed serum BLyS and APRIL in active lupus nephritis patients.MethodsSerum samples from active lupus nephritis and at 6 months post-treatment were obtained. Serum levels of BLyS and APRIL (n = 47) as well as renal mRNA expression were measured. Serum levels of both molecules and clinical data (n = 27) were available at 6 months follow-up. All biopsy-proven lupus nephritis patients were treated with similar immunosuppressive drugs.ResultsSerum levels of APRIL were associated with proteinuria (Rs = 0.44, P value < 0.01) and degree of histological activity (Rs = 0.34; P value < 0.05) whereas BLyS levels were associated with complement levels (Rs = 0.46; P value < 0.01) and dosage of immunosuppressant. Interestingly, serum APRIL as well as its intrarenal mRNA levels were associated with resistance to treatment. From the receiver operating characteristic (ROC) analysis, high levels (> 4 ng/mL) of serum APRIL predicted treatment failure with a positive predictive value of 93 percent.ConclusionAPRIL could be a potential biomarker for predicting difficult-to-treat cases of lupus nephritis.

38 keywords...

hide…